[Federal Register Volume 87, Number 17 (Wednesday, January 26, 2022)]
[Notices]
[Pages 4037-4038]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01517]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; Michael Shmilovich; <a href="/cdn-cgi/l/email-protection#63100b0e0a0f0c150e230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="d0a3b8bdb9bcbfa6bd90beb9b8feb7bfa6">[email protected]</span></a>; telephone: 301-
435-5019. A signed Confidential Disclosure Agreement may be required to 
receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Sulfur and Selenium Containing Cannabinoid Receptor Modulating 
Compounds

    Available for licensing and commercial development are sulfur- and 
selenium-containing pyrazole molecules for potentially treating 
metabolic disorders, psychiatric disorders, neurological disorders, 
pain disorders,

[[Page 4038]]

gastrointestinal disorders, cancers, inflammation-related disorders, 
substance abuse associated pathologies, and other conditions using the 
same. The filed provisional patent application includes extensive 
descriptions of the exemplary molecules and their various constituents. 
Therapeutic targets of said molecules include but are not limited to 
the cannabinoids 1 receptor, the cannabinoid 2 receptor, GPR55, GPR18, 
or GPR119. The rights pursued claim compounds, pharmaceutical 
compositions, and methods of use.
    Potential Commercial Applications:

<bullet> Pharmaceuticals
<bullet> Cancer therapy
<bullet> Inflammatory and autoimmune disease

    Development Stage:

<bullet> Early stage

    Inventors: Malliga R. Iyer, Ph.D. (NIAAA).
    Intellectual Property: HHS Reference No. E-190-2021-0; U.S. 
Provisional Patent Application No. 63/265,225 filed December 10, 2021.
    Licensing Contact: Michael Shmilovich; 301-435-5019; 
<a href="/cdn-cgi/l/email-protection#ea878389828b8f86c49982878386859c838982aa848382c48d859c"><span class="__cf_email__" data-cfemail="34595d575c5551581a475c595d585b425d575c745a5d5c1a535b42">[email protected]</span></a>.

    Dated: January 20, 2022.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2022-01517 Filed 1-25-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>